NNI for treatment of multi-drug resistant HIV

Details NNI for treatment of multi-drug resistant HIV NNI for treatment of multi-drug resistant HIV

2007-03-06

2007-03-06

Wang, Shengjun (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S580000, C514S585000

Reexamination Certificate

active

09272821

ABSTRACT:
The present invention is directed to compounds and methods suitable for the treatment of HIV infection.

REFERENCES:
patent: 4724232 (1988-02-01), Rideout et al.
patent: 5593993 (1997-01-01), Morin, Jr. et al.
patent: 5658907 (1997-08-01), Morin, Jr. et al.
patent: 5686428 (1997-11-01), Eriksson et al.
patent: 5714503 (1998-02-01), Morin, Jr. et al.
patent: 5786462 (1998-07-01), Schneider et al.
patent: WO 93/03022 (1993-02-01), None
patent: WO 99/47501 (1999-09-01), None
Ahgren, C. et al., “The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus Type 1 reverse transcriptase”,Antimicrob. Agents Chemother.,vol. 39, No. 6, pp. 1329-1335 (Jun. 1995).
Artico, M. et al., “3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): a new class of specific inhibitors of human immunodeficiency virus Type 1”,Antiviral Chem. Chemother,vol. 4, No. 6, pp. 361-368 (1993).
Baba, M. et al., “Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives”,Antiviral Res.,vol. 17, No. 4, pp. 245-264 (Apr. 1992).
Balzarini, J. et al., “2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)pyrimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase”,Proc. Natl. Acad. Sci. USA,vol. 89, No. 10, pp. 4392-4396 (May 1992).
Barlett, P.A., et al., “Caveat: A program to facilitate the structure-derived design of biologically active molecules”,Molecular Recognition in: Chemical and Biochemical Problems, Special Publication No. 78, pp. 182-196 (Apr. 1989).
Bell, F.W. et al., “Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase ihibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs”,J. Med. Chem.,vol. 38, No. 25, 4929-4936 (1995).
Blaney, J.M. et al., “A good ligand is hard to find: Automated docking methods”,Perspectives in Drug Discovery and Design,vol. 1, No. 2, pp. 301-319 (Dec. 1993)).
Böhm, H., “The computer program LUDI: A new method for the de novo design of enzyme inhibitors”,Journal of Computer-Aided Molecular Design,vol. 6, No. 1, pp. 61-78 (Feb. 1992).
Böhm, H., “LUDI: rule-based automatic design of new subsituents for enzyme inhibitor leads”,Journal of Computer-Aided Molecular Design, vol. 6, No. 6, pp. 593-606 (Dec. 1992).
Böhm, H., “The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure”,Journal of Computer-Aided Molecular Design, vol. 8, No. 3, pp. 243-256 (Jun. 1994).
Bosworth, N., et al., “Scintillation proximity assay”,Nature,vol. 341, No. 6238, pp. 167-168 (Sep. 14, 1989).
Burkert, U. et al., “Methods for the computation of molecular geometry”,Molecular Mechanics,ACS Monograph 177, American Chemical Society, Chapter 3, pp. 59-78 (1982).
Brooks, B.R. et al., “CHARMM: A program for macromolecular energy, minimization, and dynamics calculations”,J. Comp. Chem.,vol. 4, No. 2, pp. 187-217 (1983).
Cantrell, A.S. et al., “Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. synthesis and further structure-activity relationship studies of PETT analogs”,J. Med. Chem.,vol. 39, No. 21, pp. 4261-4274 (Oct. 1996).
Connolly, M.L., “Solvent-Accessible Surfaces of Proteins and Nucleic Acids”,Science,vol. 221, No. 4612, pp. 709-713 (Aug. 19, 1983).
Danel, K. et al., “Synthesis and potent Anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[2-hydroxyethoxy)methyl]-6-(phenylthio)thymine”,J. Med. Chem.,vol. 39, No. 12, pp. 2427-2431 (1996).
Danel, K. et al., “Anti-HIV active napthyl analogues of HEPT and DABO”,Acta Chemica Scandinavica,vol. 51, No. 3(S), pp. 426-430 (Mar. 1997).
Danel, K. et al., “Synthesis and Anti-HIV-1 activity of novel 2,3-dihydro-7H-thiazolo[3,2-α] pyrimidin-7-ones”,J. Med. Chem.,vol. 41, No. 2, pp. 191-198 (1998).
Das, K. et al., “Crystal Structures of 8-Cl and 9-Cl TIBO Complexed with Wild-type HIV-1 RT and 8-C1 TIBO Complexed with the Tyr181Cys HIV-1 RT Drug-resistant Mutant”,J. Mol. Biol.,vol. 264, No. 5, pp. 1085-1100 (Dec. 20, 1996).
De Clercq, E., “HIV Inhibitors Targeted at the Reverse Transcriptase”,AIDS Research and Human Retroviruses,vol. 8, No. 2, pp. 119-134 (Feb. 1992).
Ding, J., “Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors”,Nat. Struct. Biol.,vol. 2, No. 5, pp. 407-415 (May 1995).
Erice, A. et al., “Anti-Human Immunodeficiency Virus Type 1 Activity of an Anti-CD4 Immunoconjugate Containing Pokeweed Antiviral Protein”,Antimicrob. Agents Chemother.,vol. 37, No. 4, pp. 835-838 (Apr. 1993).
Esnouf, R.M. et al., “Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor”,Proc. Natl. Acad. Sci. U.S.A.,vol. 94, No. 8, pp. 3984-3989 (Apr. 15, 1997).
Goodsell, D.S. et al., “Automated Docking of Substrates to Proteins by Simulated Annealing”, PROTEINS:Structure, Function, and Genetics,vol. 8, pp. 195-202 (1990).
Greene, W.C., “The molecular biology of human immunodeficiency virus type 1 infection”,New England Journal of Medicine,vol. 324, No. 5, pp. 308-317 (Jan. 31, 1991).
Heinisch, G. et al., “The inhibitory activity of diazinyl-substituted thiourea derivatives on human immunodeficiency virus type 1 reverse transcriptase”,Antiviral Chemistry&Chemotherapy,vol. 8, No. 5, pp. 443-446 (Sep. 1997).
Hopkins, A.L. et al., “Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors”,J. Med. Chem.,vol. 39, No. 8, pp. 1589-1600 (1996).
Hsiou, Y. et al., “Structures of Tyr188Leu Mutant and Wild-type HIV-1 Reverse Transcriptase Complexed with the Non-nucleoside Inhibitor HBY 097: Inhibitor Flexibility is a Useful Design Feature for Reducing Drug Resistance”,J. Mol. Biol.,vol. 284, No. 2, pp. 313-323 (Nov. 27, 1998).
Huang, H. et al., “Structure of a Covalently Trapped Catalytic Complex of HIV-1 Reverse Transcriptase: Implications for Drug Resistance”,Science, vol. 282, No. 5394, pp. 1669-1675 (Nov. 27, 1998).
Jones, T.A. et al., “Improved Methods for Building Protein Models in Electron Density Maps and the Location of Errors in these Models”,Acta Cryst,vol. A47, Part 2, pp. 110-119 (Mar. 1, 1991).
Kohlstaedt, L.A. et al., “Crystal Structure at 3.5 Å Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor”,Science,vol. 256, pp. 1783-1790 (Jun. 26, 1992).
Kroeger Smith, M.B. et al., Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: Total energy of complexation as a predictor of drug placement and activity,Protein Science,vol. 4, pp. 2203-2222 (1995).
Kuntz, I.D. et al., “A Geometric Approach to Macromolecule-Ligand Interactions”,J. Mol. Biol.,vol. 161, No. 2, pp. 269-288 (Oct. 25, 1982).
Larder, B.A. et al., “Convergent combination therapy can select viable multidrug-resistant HIV-1in vitro”, Nature,vol. 365, No. 6445, pp. 451-453 (Sep. 30, 1993).
Luty, B.A. et al., “A Molecular Mechanics/Grid Method for Evaluation of Ligand-Receptor Interactions”,J. Comp. Chem.,vol. 16, No. 4, pp. 454-464 (Apr. 1995).
Mai, A. et al., “Synthesis and Anti HIV-1 Activity of Thio Analogues of Dihydroalkoxybenzyloxopyrimidines”,J. Med. Chem.,vol. 38, No. 17, 3258

Affiliated with

Also associated with

Rating

NNI for treatment of multi-drug resistant HIV does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with NNI for treatment of multi-drug resistant HIV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NNI for treatment of multi-drug resistant HIV will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3773391